B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.
B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.